Trial Profile
A PHASE I DOSE ESCALATION STUDY OF HYPOFRACTIONATED STEREOTACTIC RADIOTHERAPY WITH BEVACIZUMAB IN THE TREATMENT OF RECURRENT MALIGNANT GLIOMA.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary)
- Indications Anaplastic astrocytoma; Glioblastoma; Glioma; Oligodendroglioma
- Focus Adverse reactions
- 20 Nov 2019 Status changed from active, no longer recruiting to completed.
- 04 Apr 2019 Planned End Date changed from 1 Jul 2019 to 1 Jul 2020.
- 04 Apr 2019 Planned primary completion date changed from 1 Jul 2019 to 1 Jul 2020.